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Abstract
Background/Aims—Our study examined whether patient characteristics, beliefs, and decision-
making styles were associated with uptake of genomic testing for breast cancer recurrence risk.
Methods—Participants were 132 early-stage breast cancer patients eligible for the Oncotype DX
genomic test. We interviewed patients in 2009–2010 and obtained information from medical
charts.
Results—Half of women eligible for genomic testing for breast cancer recurrence risk received
it. The most common reason for not getting the test was that women’s physicians did not offer it
(80%). Test recipients were more likely to be unsure about receiving chemotherapy treatment
compared to women who did not receive the test (p<.05). Women who received the test had less
advanced disease pathologies, recalled a lower objective recurrence risk, perceived lower
recurrence risk and were slightly younger (all p<.05). Most women who described their decision-
making style as active received the test (75%) whereas few women who described their style as
passive received the test (12%) (p<.01).
Conclusion—In the university clinic we studied, genomic testing appeared to more common
among patients who may benefit most from the information provided by results, but confirmation
in larger studies is needed.
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INTRODUCTION
Genomic testing has become an important part of clinical cancer care. One increasingly used
test, Oncotype DX, estimates 10-year risk of breast cancer recurrence and predicts
chemotherapy benefit among early stage, hormone-receptor positive patients by examining
the activity of 21 genes in breast tumors [1, 2]. Test results offer additional insight beyond
standard clinicopathological markers such as tumor size and grade for assessing risk, and
offer more precise risk estimates [3–6]. One of the potential promises of Oncotype DX
testing is to allow women with low recurrence risk scores to safely forgo chemotherapy and
its potential side effects. A recent systematic review of 10 studies of the impact of Oncotype
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DX test results on clinical treatment found that test results were associated with changes in
about 20% to 40% of treatment recommendations, most often in the direction of declining
adjuvant chemotherapy [7].
Guidelines from several major professional groups, including the National Comprehensive
Cancer Network, recommend that physicians consider Oncotype DX testing for eligible
women. Patients also have a strong interest in genomic testing to assess their breast cancer
recurrence risk [8]. These factors likely have contributed to the rapid adoption of the test.
However, little is known about determinants of which eligible patients receive this test in
clinical settings. It is unclear whether genomic testing is being offered by physicians to
women who may benefit from the information provided by test results, whether there are
socio-demographic disparities in uptake of the test, and the extent to which patient
preferences and beliefs influence test receipt.
Our study team conducted individual interviews with women who were undergoing
treatment for early stage breast cancer and met eligibility criteria to receive Oncotype DX
testing. The purpose of our study was to examine whether medical and demographic
characteristics, beliefs, and decision-making styles of women eligible for the Oncotype DX
test were associated with receipt of the test. We also assessed patient-reported reasons for
not getting the test.
METHODS
Participants and recruitment
Participants were women being treated for early-stage breast cancer at the University of
North Carolina Breast Clinic (Chapel Hill, NC) between May 2009 and November 2010,
who were eligible to receive genomic recurrence risk testing by Oncotype DX (diagnosed
with stages I or II, hormone-receptor positive breast cancer). We obtained a temporary
waiver of HIPAA authorization to determine women’s receipt of the test prior to
approaching them for participation. We included both node-negative and node-positive
women, as studies have validated the test for both groups of women [1, 3]. We excluded
women who were non-English speaking, were incarcerated, had a second primary cancer
diagnosis or other life-threatening co-morbid disease, or had a history of a serious
psychiatric diagnosis. Approaching these women for participation would have been
unadvisable by physicians due to other health concerns or their limited ability to
comprehend study materials.
For women who received the genomic test, we attempted to survey them in clinic during the
appointment at which they received their test results. For women who did not receive the
test, we surveyed them at their next scheduled medical oncology appointments after their
initial visit to the breast clinic. We mailed study materials to women who consented to be in
the study but did not complete baseline questionnaires in clinic.
Patients read and signed a written informed consent form. They had the option to complete a
HIPAA authorization form to allow a review of their medical records to abstract additional
information on their cancer (e.g. stage, grade). Women received $15 and a parking pass for
participating. The University of North Carolina Institutional Review Board approved the
study.
Measures
We collected patient data primarily through study questionnaires and supplemented data
collection through review of medical charts for patients who provided consent. All but 6
women consented to review of their medical charts. Three team members abstracted data
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from medical charts and a program manager reviewed abstracted chart information for
accuracy. Study questionnaires varied slightly according to whether or not women received
the test.
Medical chart review—For patients who consented to medical chart review, study staff
recorded pathology information (tumor stage and grade, number of positive nodes),
menopausal status, number of co-morbidities and other information related to prognosis and
treatment. We used patient pathology information to calculate women’s 10-year risk of
distant cancer recurrence using Adjuvant! Online version 7. For patients who refused
medical chart review, these data were treated as missing.
Demographics—The questionnaires assessed patients’ demographic characteristics (race,
education, income, health insurance status, employment status, and marital status). The
questionnaires assessed numeracy with a validated three item scale, [9] and we
dichotomized responses as “low” (0–1 correct items) or “high” (2–3 correct items). A single,
validated health literacy item assessed how often respondents need help with written health-
related materials [10]. We dichotomized responses as “high” literacy (“never” or “rarely”
needs help) and “low” literacy (“sometimes” to “always” needs help).
Plans for treatment and recurrence risk—The questionnaire assessed patients’ plans
to receive chemotherapy treatment in the future (“yes”, “no” or “unsure”). Three
questionnaire items assessed women’s beliefs about their recurrence risk. One risk
perception item assessed patients’ recall of what their doctors said their recurrence risk was
by asking, “What did your doctor say was the chance of your breast cancer coming back in
the next 10 years based on the test?” A 5-point response scale ranged from “very low
chance” to “very high chance”; these response options were similar to the 3 Oncotype DX
recurrence risk categories. Another risk perception item assessed patients’ recall of their
numerical recurrence risk and read “Here is the same question asked in a different way.
What did your doctor say was the percent chance that your cancer will come back in the next
10 years based on the test?” The questionnaire provided a space to fill in a percentage (0–
100%). For women who did not receive the test, these two risk perception items did not
include the phrase “based on the test”. A third risk perception item assessed patients’
perceived recurrence risk: “Aside from what your doctor said, what do you think is your
percent chance of your breast cancer coming back in the next 10 years?” The questionnaire
provided a space to fill in a percentage (0–100%).
Psychosocial variables—The questionnaire assessed breast cancer worry using
previously validated items asking how often women worried about or thought about their
chances of getting breast cancer again and how often these thoughts affected their mood or
ability to engage in daily activities [11]. The 4-point response scale ranged from “rarely or
never” to “(almost) all the time.” We calculated a mean for the 4 items with higher scores
reflecting more worry. The questionnaire assessed women’s beliefs that their breast cancer
could recur using one item that read “Breast cancer could possibly come back in another part
of my body.” This item had a 5-point response scale, coded such that higher scores reflected
a stronger belief that their cancer could come back. One item assessed perceived
effectiveness of chemotherapy treatment: “How much do you think chemotherapy will help
lower the chance of your breast cancer coming back?” The 5 point response scale ranged
from “none at all” to “completely”, coded such that higher scores reflected higher perceived
effectiveness. Two items assessed whether women felt their standard test results (e.g. tumor
stage and size) could be trusted and were accurate. The 5 point response scale ranged from
“strongly disagree” to “strongly agree”, coded such that higher scores reflected greater trust
and perceived accuracy.
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One item assessed women’s preferred role in treatment decision making [12] and had the
following response options: “I prefer to make the final selection about which treatment I will
receive”; “I prefer to make the final selection of my treatment after seriously considering my
doctor’s opinion”; “I prefer that my doctor and I share the responsibility for deciding which
treatment is best for me”; “I prefer that my doctor makes the final decision about what
treatment will be used, but seriously considers my opinion”; and “I prefer to leave all
decisions regarding my treatment to my doctor.” Following standard methods[13–15], we
coded the first two responses as indicating “active decision-making”, the third as “shared
decision-making”, and the last two as “passive decision-making”
Reasons for not getting the test—For women who did not receive the test, a brief
description of Oncotype DX appeared at the end of the questionnaire followed by a question
on whether women had heard about the test before and whether their doctors had offered
them the test. The questionnaire also listed other possible reasons for not receiving the test
(e.g., I already knew I wanted chemotherapy) and an open-ended “other” response option.
Women could check as many reasons as applied.
Data analysis
Percentages in text refer to the final sample (n=132) unless noted due to missing data. We
used bivariate logistic regression to model the probability of receiving the test; analyses
provided unadjusted odds ratios and 95% confidence intervals. We then conducted
sensitivity analyses excluding 23 women who were node-positive according to their medical
charts, because of questions regarding the usefulness of genomic testing for this group
(node-positive women often receive chemotherapy treatment). All tests were two-tailed with
a critical alpha of .05. We analyzed data using SAS v 9.2 (Cary, NC).
RESULTS
Of 246 women eligible to receive Oncotype DX testing, 225 were eligible for our study
(Figure 1). Of these women, 143 participated in the study (64%). Participation was higher
for women who received the test (70%, 66/94) compared to those who did not (51%,
77/151). Women completed the questionnaires in clinic (22%, 31/143), at home (56%,
80/143), or in both locations (22%, 32/143). We excluded 11 women from analyses who
received neoadjuvant chemotherapy according to their medical charts, as these women
generally should not be offered the test. The final sample of 132 women was predominately
white (88%), insured (95%) and married (69%) (Table 1). About one-half worked for pay
(48%), and over one-half had annual household incomes over $60K (61%) and had college
degrees (64%).
Sixty six women (50%) received genomic testing and 66 (50%) did not receive the test.
Women who did not receive the test often reported that their doctors did not offer them the
test (80%, 53/66) and that they had not heard of the test (65%, 43/66) (Table 2). Other
reasons were that women already knew that they either wanted (14%, 9/66) or did not want
(14%, 9/66) chemotherapy or their doctors advised against the test, because the information
would not have been useful (8%, 5/66). Cost of the test was not a common concern for this
population (2%, 1/66).
Demographic and medical characteristics
Receipt of the test did not differ by demographic characteristics (all p>.05; Table 1), with
the exception of slightly younger age for women who received the test (Table 3, p=.01).
Women who received and did not receive the test were about 3 months post-diagnosis
according to medical charts (Table 3). Women were less likely to receive the test if they
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were diagnosed with slightly later-staged cancers (stage IIb compared to I), were post-
menopausal (compared to pre-menopausal), had one or more positive nodes or had medium-
sized tumors (compared to small) (all p<.05). Women who received the test were similar to
those who did not with regard to receipt of breast conserving surgery, mastectomy,
radiation, level of comorbidity, tumor grade, progesterone receptor status and self-reported
family history of breast cancer (all p>.10).
Risk of recurrence
Risk of recurrence scores estimated through Adjuvant! Online were similar for women who
received and did not receive the test (Table 3, mean=28% and 32% respectively). Women’s
self-reported risk category (e.g. “low”) as conveyed to them by their physicians was not
associated with receipt of the test. However, women who received the test recalled slightly
lower numerical recurrence risk scores (e.g., 0–100%) as conveyed to them by their
physicians compared to those who did not receive the test (mean= 10% and 16%
respectively, p=.05). Only about one-half of women (55%; 73/132) said they knew their
numerical recurrence risk number as reported by their physicians, whereas more women
(80%; 106/132) recalled being told their recurrence risk category. Women who received the
test perceived their recurrence risk as lower than those who did not receive the test
(mean=12% and 18% respectively, p =.05). Also, women who received the test less strongly
endorsed the belief that their cancers could come back than women who did not receive the
test (p=.02).
Psychosocial characteristics
Women who said they were “unsure” about getting chemotherapy treatment were much
more likely to get the test compared to women who said they already planned on getting
chemotherapy (Table 4, 87% and 37% respectively, p<.01). Compared to women who
described their decision-making style as passive, women who described their decision-
making styles as active were dramatically more likely to have received the test (Table 4,
12% for passive vs. 75% for active, p<.01). Additional analyses showed that age, race,
education and measures of recurrence risk were not associated with preferred decision-
making styles (all p>.05). Women who received the test also reported slightly lower trust
and perceived accuracy in their standard (non-genomic) test results than women who did not
receive the test (p=.03 and p=.05 respectively). Both groups of women reported equal levels
of worry about breast cancer and belief in the effectiveness of chemotherapy (p>.05).
Sensitivity Analyses
We conducted the same analyses described above excluding the 23 lymph node-positive
women, given questions about the appropriateness of the test for this group. As expected,
exclusion of node-positive women explained many of the clinical differences between the
two cohorts: after exclusion of the node-positive patients, women who received and did not
receive the test no longer differed according to the recurrence risk they recalled their doctors
telling them (p=.29), perceived recurrence risk (p=.34), or cancer stage (p=.45 for
comparison between stage IIb and I patients). However, even after exclusion of node-
positive patients, differences in the other psychosocial variables remained. Women who got
the test still reported less concern about their cancer coming back (p<.05), and less trust and
perceived accuracy in their standard test results (both p<.05) compared to those who did not
get the test. Women who got the test were still more likely to report being “unsure” about
receiving chemotherapy treatment (p<.05) and were dramatically more likely to describe
themselves as active (p<.01) or shared (p<.05) decision makers.
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Findings from our study in a single university clinic suggest that women receiving genomic
testing were those who may benefit the most from the information provided by the test
results, but confirmation in a larger study of multiple clinics is needed. Women who, at the
time of their surveys, said they were unsure about whether or not to get chemotherapy were
much more likely to have had the test than women who had already decided to have the
treatment. This finding is appropriate, as women who are uncertain about treatment may
derive more benefit from the test in terms of decision making support compared to women
who have already made treatment decisions. Among patients who did not receive the test,
80% said the reason was because their doctor did not offer it. This finding may suggest that
physicians are reluctant to order or discuss the test with patients who have already made
treatment decisions or reluctant to offer the test to women they perceived a priori to be at
higher risk, such as node-positive patients. This hypothesis is supported by a qualitative
study of physicians where most said they would not order the test if a patient was certain to
have or forgo chemotherapy [16]. Alternatively, women who did not recall being offered the
test may have received unclear information or not understood what test they were being
offered, as for instance when the brand name of the test was not mentioned. Whether
patients who did not recall being offered the test in the current study could have benefited
from information provided by the results is unclear.
Test recipients recalled that their doctors conveyed lower recurrence risk to them and
perceived lower recurrence risk, compared to those who did not get the test. This finding
might suggest that women who believe they have a lower recurrence risk and thus a more
favorable prognosis are more likely to get the test, perhaps using test results to inform
potential decisions to forgo chemotherapy. Conversely, women who have higher perceived
recurrence risk might already have decided to have chemotherapy; test results might not
change their treatment decisions. However, our cross-sectional data preclude us from
determining whether risk beliefs motivated behavior. While our objective measure of
recurrence risk (Adjuvant Online! scores that incorporated non-genomic pathology
information) did not differ between women receiving and not receiving genomic testing, we
found that those who got the test had slightly less advanced disease according to some
pathological markers such as stage and node involvement. Our sensitivity analyses
demonstrated that when node-positive women were removed from the study sample, the
difference between tested and untested women in clinical measures largely disappeared.
This result may indicate that physicians or patients remain uncomfortable relying on the
results of genomic testing to forgo chemotherapy in a group usually categorized as at high
risk of recurrence.
Of interest was the finding that, regardless of node-involvement, women who received the
test reported slightly lower trust and perceived accuracy in their standard non-genomic
results for recurrence risk compared to women who did not receive the test. These findings
are consistent with evidence showing that genomic testing provides more precise recurrence
risk estimates compared to standard non-genomic markers [5, 17] and with our previous
research suggesting that women place more emphasis on genomic over standard risk
information when test results conflict [18]. Also regardless of node-involvement, women
who received the test were less concerned that their cancer would come back compared to
women who did not receive the test. However, the sources of this finding are unclear.
Women who received the test likely would have discussed recurrence risk during their clinic
appointments, perhaps receiving some reassurance from their doctors.
Consistent with an increased emphasis on patient participation in medical decisions, our
study found that most participants said they preferred some role in treatment-related
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decisions. However, the robust association of patient decision-making style with uptake of
genomic testing warrants consideration. Uptake of the test was dramatically higher for
women who reported an active compared to passive decision making style. Over 70% of
women who said they preferred a more active role in their treatment decisions received the
test; in comparison, only 12% of women who said they preferred that their physicians make
decisions about their treatment received the test. While studies show that younger age and
higher educational status are consistent predictors of the desire to participate in shared
decision making [19], these factors were not associated with decision making styles for our
study, suggesting that other psychosocial factors may account for women’s decision-making
preferences. However, caution must be used in interpreting the association between test
uptake and decision-making style. Our analyses used cross-sectional data, which precludes
us from knowing, for example, whether women’s decision making styles influenced uptake
or if the behavior of receiving the test influenced responses about preferred decision-making
styles. Regardless, best practices for clinical communication between physicians and
patients about the utility of such tests remains unclear [16].
There were minimal socio-demographic disparities in uptake of genomic testing for this
population of early stage breast cancer patients. Women who received the test did not differ
by race, income, or education, although women who received the test were slightly younger
in age than those who did not receive the test. However, these findings should be interpreted
with caution, as our study was limited to a single institution, and almost all study
participants had health insurance. Also, we were not able to assess whether study
participants differed from other patients as this information was not available to us. Thus, it
is possible that the absence of socio-demographic differences in uptake for our study
population is obscured due to low participation by certain subgroups. Other studies have
pointed to potential racial and ethnic disparities in uptake of genomic testing [20–22]. The
question of whether the test is being applied equivalently among diverse populations
remains an area of future research.
Our study is one of the few to describe uptake of genomic testing for breast cancer
recurrence risk in a clinical setting and was successful in recruiting women who did and did
not get the test. Our findings suggest that women receiving genomic testing for breast cancer
recurrence were those who may benefit the most from the information provided by the test
results, although future research on use of such tests in more diverse settings and patient
populations is warranted.
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Other 15/130(12) 6/15 (40)
White 115/130 (88) 59/115 (51) 1.58 (0.53, 4.73)
Marital Status
Not married 40/130 (31) 17/40 (43)
Married/living as married 90/130 (69) 49/90 (54) 1.61 (0.76, 3.43)
Education
Less than college 46/129 (36) 20/46 (44)
College or more 83/129 (64) 46/83 (55) 1.62 (0.78, 3.34)
Annual household income
<$60,000 47/120 (39) 25/47 (53)
≥$60,000 73//120 (61) 35/73 (48) 0.81 (0.39, 1.69)
Worked for pay
No 66/128 (52) 30/66 (45)
Yes 62/128 (48) 36/62 (58) 1.66 (0.83, 3.34)
Insured
No 7/130 (5) 3/7 (43)
Yes 123/130 (95) 63/123 (51) 1.40 (0.30, 6.52)
Literacy
Low 17/131 (13) 5/17 (29)
High 114/131 (87) 61/114 (54) 2.76 (0.91, 8.36)
Numeracy
Low 39/132 (30) 20/39 (51)
High 93/132 (70) 46/93 (49) 0.93 (0.44, 1.96)
Note. Ns differ due to missing data. None of the ORs are statistically significant.
a
Modeling probability of receiving the test compared to not having received the test.
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Table 2
Reasons patients gave for not having received the test (n=64)
%
Doctor did not offer the test 80
Patient had not heard of the test 65
Patient already knew she wanted chemotherapy 14
Patient already knew she did not want chemotherapy 14
Doctor said the test was not necessary/ information was not needed 8
Could not afford 2
Don’t know 14
Other 6
Note. Patients checked all reasons that applied. 2 subjects did not respond to these survey items.
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mean (SD) mean (SD)
Medical
Age at diagnosis, years (n=126) 62.2 (11.1) 57.5 (10.2) 0.96 (0.93, 0.99)*
Months since diagnosis, median (n=126) 3.0 (35.1) 3.0 (31.3) n/a
Recurrence Risk
Objective recurrence risk, from Adjuvant! Online, 0–100% (n=126) 31.7 (16.3) 28.3 (11.3) 0.98 (0.96, 1.01)
Patient reported recurrence risk, category (n=106) 1.8 (.70) 1.7 (.68) 0.77 (0.44, 1.35)
Patient reported recurrence risk, 0–100% (n=73) 15.7 (16.3) 10.0 (3.5) 0.98 (0.95, 1.00)*
Perceived recurrence risk, 0–100% (n=126) 18.4 (22.4) 11.7 (12.7) 0.98 (0.95, 1.00)*
Psychosocial
Belief that cancer could come back (n=129) 4.0 (0.87) 3.5 (1.11) 0.64 (0.44, 0.92)*
Worry about breast cancer (n=128) 1.7 (0.64) 1.5 (0.56) 0.67 (0.37, 1.22)
Trust in standard (non-genomic) test results (n=125) 4.1 (.80) 3.8 (.65) 0.58 (0.35, 0.95)*
Perceived accuracy of standard (non-genomic) test results (n=124) 4.1 (.81) 3.8 (.61) 0.60 (0.36, 1.00)*
Perceived effectiveness of chemotherapy (n=124) 2.8 (1.22) 2.5 (1.13) 0.82 (0.60, 1.12)
Note. Ns differ due to missing data or withheld consent to review medical chart.
a
Modeling probability of receiving the test compared to not receiving the test
*
p <.05
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Table 4







n (%) n (%)
Planning to get chemotherapy
No 69/130 (53) 36/69 (52) 1.86 (0.87, 3.99)
Unsure 15/130 (12) 13/15 (87) 11.09 (2.23, 55.17)**
Yes 46/130 (35) 17/46 (37) Ref
Stage
I 72/126 (57) 42/72 (58) Ref
IIa 38/126 (30) 19/38 (50) 0.71 (0.32, 1.57)
IIb 16/126 (13) 4/16 (25) 0.24 (0.07, 0.81)*
Menopause status
Pre 22/125 (18) 17/22 (77) Ref
Current 8/125 (6) 7/8 (88) 2.06 (0.20, 20.99)
Post 95/125 (76) 41/95 (43) 0.22 (0.08, 0.66)**
Positive lymph nodes
0 103/126 (82) 58/103 (56) Ref
1–3 23/126 (18) 7/23 (30) 0.34 (0.13, 0.90)*
Tumor size
≤1cm 33/124 (27) 11/33 (33) Ref
1.1–2 cm 52/124 (42) 36/52 (69) 4.50 (1.77,11.44)*
>2 cm 39/124 (31) 17/39 (44) 1.55 (0.59, 4.04)
Patient’s decision-making style
Passive 26/130 (20) 3/26 (12) Ref
Shared 64/130 (49) 33/64 (52) 8.16 (2.23, 29.92)*
Active 40/130 (31) 30/40 (75) 23.00 (5.67, 93.23)**
Note. Ns differ due to missing data or withheld consent to review medical chart.
a





Public Health Genomics. Author manuscript; available in PMC 2014 July 30.
